Patents by Inventor Frank STEGMEIER

Frank STEGMEIER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • THERAPEUTIC COMBINATIONS COMPRISING UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS AND POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS
    Publication number: 20230277533
    Abstract: The present disclosure provides therapeutic combinations comprising (i) a ubiquitin-specific-processing protease 1 (USP1) inhibitor and (ii) a poly ADP-ribose polymerase (PARP) inhibitor, or a pharmaceutically acceptable salt, hydrate, solvate, amorphous solid, or polymorph thereof, wherein the USP1 inhibitor comprises (I), (II), or (III), or pharmaceutically acceptable salts, hydrates, solvates, amorphous solids, or polymorphs thereof. The present disclosure is also directed to the use of the combinations to inhibit a USP1 and/or PARP protein and/or to treat a disorder responsive to the inhibition of USP1 and/or PARP proteins and USP1 and/or PARP activity. The combinations of the present disclosure are especially useful for treating cancer.
    Type: Application
    Filed: February 12, 2021
    Publication date: September 7, 2023
    Inventors: Andrew Alistair WYLIE, Solomon Martin SHENKER, Pamela Jean SULLIVAN, Frank STEGMEIER, Anne Louise CADZOW, Hanlan LIU, Kerstin Wolf SINKEVICIUS
  • COMBINATION GENE TARGETS FOR IMPROVED IMMUNOTHERAPY
    Publication number: 20200347386
    Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.
    Type: Application
    Filed: February 4, 2020
    Publication date: November 5, 2020
    Inventors: Micah BENSON, Michael SCHLABACH, Gregory KRYUKOV, Anne Louise CADZOW, Isabelle Fleur LE MERCIER, Frank STEGMEIER
  • ORGANIC COMPOSITIONS TO TREAT HSF1-RELATED DISEASES
    Publication number: 20190323008
    Abstract: The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer autoimmune and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.
    Type: Application
    Filed: June 24, 2019
    Publication date: October 24, 2019
    Inventors: Jinyun Chen, Kalyani Gampa, Dieter Huesken, Frank Stegmeier, Mark Stump, Chandra Vargeese, Jan Weiler, Wenlai Zhou
  • Organic compositions to treat HSF1-related diseases
    Patent number: 10329563
    Abstract: The present disclosure relates to methods of treating heat stock factor 1 (HSF1)-related diseases such as cancer, autoimmune and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: June 25, 2019
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Jinyun Chen, Kalyani Gampa, Dieter Huesken, Frank Stegmeier, Mark Stump, Chandra Vargeese, Jan Weiler, Wenlai Zhou
  • ORGANIC COMPOSITIONS TO TREAT HSF1-RELATED DISEASES
    Publication number: 20170298354
    Abstract: The present disclosure relates to methods of treating heat stock factor 1 (HSF1)-related diseases such as cancer, autoimmune and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.
    Type: Application
    Filed: May 5, 2017
    Publication date: October 19, 2017
    Inventors: Jinyun Chen, Kalyani Gampa, Dieter Huesken, Frank Stegmeier, Mark Stump, Chandra Vargeese, Jan Weiler, Wenlai Zhou
  • ORGANIC COMPOSITIONS TO TREAT HSF1-RELATED DISEASES
    Publication number: 20160032284
    Abstract: The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer, autoimmune and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.
    Type: Application
    Filed: August 30, 2012
    Publication date: February 4, 2016
    Applicant: Arrowhead Research Corportation
    Inventors: Jinyun CHEN, Kalyani GAMPA, Dieter HUESKEN, Frank STEGMEIER, Mark STUMP, Chandra VARGEESE, Jan WEILER, Wenlai ZHOU